“Off-the-Shelf” Engineered Stem Cell Therapy for Glioblastoma Prolongs Survival in Animal Model

Researchers at Brigham and Women’s Hospital have designed a biologic agent, dubbed EnMSCBif, to bind to death receptor 5 (DR5) on the surface of glioblastoma cells and trigger extrinsic programmed cell death. They report on the high potential of EnMSCBif to be translated into clinical use.
Read More...